MedPath

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

Phase 2
Completed
Conditions
Sexual Arousal Disorder
Registration Number
NCT00425256
Lead Sponsor
Palatin Technologies, Inc
Brief Summary

This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  • Post menopausal and in general good health
  • In a stable relationship with a male partner for at least 6 months
  • Willing to attempt sexual activity once a week with your partner
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (20)

Medical Affiliated Research Center

🇺🇸

Huntsville, Alabama, United States

Quality of Life Medical & Research Center, LLC

🇺🇸

Tucson, Arizona, United States

University of California, Department of Family and Preventative Medicine

🇺🇸

LaJolla, California, United States

Downtown Women's Health Care

🇺🇸

Denver, Colorado, United States

Coastal Connecticut Research

🇺🇸

New London, Connecticut, United States

South Florida Medical Research

🇺🇸

Aventura, Florida, United States

Clinical Study Center

🇺🇸

Ft. Myers, Florida, United States

Center For Marital and Sexual Health of South Florida

🇺🇸

West Palm Beach, Florida, United States

Northeast Indiana Research

🇺🇸

Fort Wayne, Indiana, United States

Center for Sexual Medicine at Sheppard Pratt

🇺🇸

Baltimore, Maryland, United States

Scroll for more (10 remaining)
Medical Affiliated Research Center
🇺🇸Huntsville, Alabama, United States
© Copyright 2025. All Rights Reserved by MedPath